Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by GENFIT S.A.
< Previous
1
2
Next >
GENFIT Announces 2026 Financial Calendar
January 07, 2026
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N
January 06, 2026
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
December 10, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Announces Appointment of new Chief Medical Officer
November 27, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
November 20, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
November 20, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
November 10, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
November 10, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
October 30, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025
October 28, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
September 22, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
September 19, 2025
From
GENFIT S.A.
Via
GlobeNewswire
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
July 08, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
June 17, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Reports First Quarter 2025 Financial Information
May 22, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
May 20, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
May 14, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents
May 07, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT to Present Latest ACLF Research at EASL Congress 2025
May 05, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
April 29, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
April 28, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
April 24, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders
March 20, 2025
From
GENFIT S.A.
Via
GlobeNewswire
Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs
March 10, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Announces Revenues and Cash Position as of December 31, 2024
February 27, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting
February 21, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders
February 14, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders
February 10, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
February 06, 2025
From
GENFIT S.A.
Via
GlobeNewswire
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
January 30, 2025
From
GENFIT S.A.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today